A Rabbit Langendorff Heart Proarrhythmia Model: Predictive Value for Clinical Identification of Torsades De Pointes.
From: Safety Pharmacology, Safety Assessment UK, AstraZeneca R&D, Macclesfield, Cheshire, UK. chris.lawrence@astrazeneca.com
British journal of pharmacology
- Publish Date: Dec 2006
- ISSN: 0007-1188
- Volume: 149
- Issue: 7
- Pages: 845-60
- Medium: Print
- Language: English
- Citation (JAMA): Lawrence C L, Bridgland-Taylor M H, Pollard C E, et al. A Rabbit Langendorff Heart Proarrhythmia Model: Predictive Value for Clinical Identification of Torsades De Pointes.. Br. J. Pharmacol. Dec 2006;149:845-60
Abstract
BACKGROUND AND PURPOSE: The rabbit isolated Langendorff heart model (SCREENIT) was used to investigate the proarrhythmic potential of a range of marketed drugs or drugs intended for market. These data were used to validate the SCREENIT model against clinical outcomes. EXPERIMENTAL APPROACH: Fifty-five drugs, 3 replicates and 2 controls were tested in a blinded manner. Proarrhythmia variables included a 10% change in MAPD(60), triangulation, instability and reverse frequency-dependence of the MAP. Early after-depolarisations, ventricular tachycardia, TdP and ventricular fibrillation were noted. Data are reported at nominal concentrations relative to EFTPC(max). Proarrhythmic scores were assigned to each drug and each drug category. KEY RESULTS: Category 1 and 2 drugs have the highest number of proarrhythmia variables and overt proarrhythmia while Category 5 drugs have the lowest, at every margin. At 30-fold the EFTPC(max), the mean proarrhythmic scores are: Category 1, 101+/-24; Category 2, 101+/-14; Category 3, 72+/-20; Category 4, 59+/-16 and Category 5, 22+/-9 points. Only drugs in Category 5 have mean proarrhythmic scores, below 30-fold, that remain within the Safety Zone. CONCLUSIONS AND IMPLICATIONS: A 30-fold margin between effects and EFTPC(max) is sufficiently stringent to provide confidence to proceed with a new chemical entity, without incurring the risk of eliminating potentially beneficial drugs. The model is particularly useful where compounds have small margins between the hERG IC(50) and predicted EFTPC(max). These data suggest this is a robust and reliable assay that can add value to an integrated QT/TdP risk assessment.
Mesh Headings (Keywords): Animals, Arrhythmias, Cardiac, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical, Drugs, Investigational, Electrocardiography, Ether-A-Go-Go Potassium Channels, Female, Heart, Humans, Long QT Syndrome, Membrane Potentials, Models, Animal, Predictive Value of Tests, Rats, Reproducibility of Results, Risk Assessment, Time Factors, Torsades de Pointes
Check for Full Text / PubMed Unique Identifier (PMID): 17031389
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.